Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11037)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2015 (publication date) through Apr 16, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015; 21(41): 11621-11635 [PMID: 26556991 DOI: 10.3748/wjg.v21.i41.11621] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i41/11621.htm |
| Number | Citing Articles |
| 1 |
Giandomenico Roviello, Catalano Martina, Costanza Winchler, Irene De Gennaro Aquino, Francesca Papa, Eleonora Buttitta, Gemma Rossi, Lorenzo Antonuzzo. Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy. Journal of Gastrointestinal Cancer 2023; 54(3): 802 doi: 10.1007/s12029-022-00865-5
|
| 2 |
Raghav Sundar, Nesaretnam Barr Kumarakulasinghe, Yiong Huak Chan, Kazuhiro Yoshida, Takaki Yoshikawa, Yohei Miyagi, Yasushi Rino, Munetaka Masuda, Jia Guan, Junichi Sakamoto, Shiro Tanaka, Angie Lay-Keng Tan, Michal Marek Hoppe, Anand D. Jeyasekharan, Cedric Chuan Young Ng, Mark De Simone, Heike I. Grabsch, Jeeyun Lee, Takashi Oshima, Akira Tsuburaya, Patrick Tan. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2022; 71(4): 676 doi: 10.1136/gutjnl-2021-324060
|
| 3 |
Mingzhe Li, Zidan Zhao, Tsz Kin Mak, Xiaoqun Wang, Jingyao Chen, Hui Ren, Zhiwei Yu, Changhua Zhang. Neutrophil extracellular traps−related signature predicts the prognosis and immune infiltration in gastric cancer. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1174764
|
| 4 |
Chang-Fei Li, Li-Li Lian, Qiu-Ru Li, Yan Jiao. Immunotherapy for metastatic gastric cancer. World Journal of Gastrointestinal Surgery 2024; 16(11): 3408-3412 doi: 10.4240/wjgs.v16.i11.3408
|
| 5 |
Beatrice Riccò, Giulio Martinelli, Camilla Bardasi, Massimo Dominici, Andrea Spallanzani, Massimiliano Salati. Optimizing the Continuum of Care in Gastric Cancer. OncoTargets and Therapy 2023; : 995 doi: 10.2147/OTT.S365505
|
| 6 |
Binay Kumar Shah, Amit Khanal, Yvonne Hewett. Second Primary Malignancies in Adults with Gastric Cancer – A US Population-Based Study. Frontiers in Oncology 2016; 6 doi: 10.3389/fonc.2016.00082
|
| 7 |
Meghana Korikani, Mohammed Qudrathulla Khan Quadri, Ravikanth Vishnubhotla, Smita C. Pawar, Rama Krishna Kancha. Biomedical Aspects of Solid Cancers. 2024; : 41 doi: 10.1007/978-981-97-1802-3_4
|
| 8 |
Min Joo Yang, Young Jin Choi, Hyo Jeong Kim, Do Young Kim, Young Mi Seol. Treatment with Ramucirumab-paclitaxel in a metastatic gastric cancer patient undergoing hemodialysis. Medicine 2021; 100(7): e24795 doi: 10.1097/MD.0000000000024795
|
| 9 |
Pengbo Deng, Chengping Hu, Cen Chen, Liming Cao, Qihua Gu, Jian An, Ling Qin, Min Li, Baimei He, Juan Jiang, Huaping Yang. Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial. Cancer Medicine 2022; 11(19): 3563 doi: 10.1002/cam4.4736
|
| 10 |
Yangyang Wang, Jiping Zeng, Jianyong Pan, Xue Geng, Yansong Liu, Jing Wu, Ping Song, Ying Wang, Jihui Jia, Lixiang Wang. MicroRNA-200c is involved in proliferation of gastric cancer by directly repressing p27 Kip1. Biochemistry and Biophysics Reports 2016; 8: 227 doi: 10.1016/j.bbrep.2016.09.007
|
| 11 |
Kholood Abid Janjua, Raheem Shahzad, Adeeb Shehzad. Cancer Biomarkers in Diagnosis and Therapeutics. 2022; : 277 doi: 10.1007/978-981-16-5759-7_11
|
| 12 |
Roy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, Emiliano Calvo, Luis Paz-Ares, Philippe A Cassier, Johanna Bendell, Nicolas Penel, Matthew G Krebs, Juan Martin-Liberal, Nicolas Isambert, Andres Soriano, Martin Wermke, Jennifer Cultrera, Ling Gao, Ryan C Widau, Gu Mi, Jin Jin, David Ferry, Charles S Fuchs, Daniel P Petrylak, Ian Chau. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. The Lancet Oncology 2019; 20(8): 1109 doi: 10.1016/S1470-2045(19)30458-9
|
| 13 |
Yu-Chang Chuang, Hsin-Yi Wu, Yu-Ling Lin, Shey-Cherng Tzou, Cheng-Hsun Chuang, Ting-Yan Jian, Pin-Rong Chen, Yuan-Ching Chang, Chi-Hsin Lin, Tse-Hung Huang, Chao-Ching Wang, Yi-Lin Chan, Kuang-Wen Liao. Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer. Biological Procedures Online 2018; 20(1) doi: 10.1186/s12575-018-0073-x
|
| 14 |
Panpan Zhang, Zhendong Chen, Si Shi, Zhiping Li, Feng Ye, Lijie Song, Yanqiao Zhang, Fei Yin, Xing Zhang, Jianming Xu, Ying Cheng, Weiguo Su, Michael Shi, Songhua Fan, Panfeng Tan, Chen Zhong, Ming Lu, Lin Shen. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer. Cancer Immunology, Immunotherapy 2024; 73(7) doi: 10.1007/s00262-024-03677-7
|
| 15 |
Florian Lordick, Peter Thuss-Patience, Michael Bitzer, Daniel Maurus, Ugur Sahin, Özlem Türeci. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. Journal of Cancer Research and Clinical Oncology 2023; 149(9): 5937 doi: 10.1007/s00432-022-04459-3
|
| 16 |
K. Debiec, J. Wydmanski. Introduction to Cancer Metastasis. 2017; : 137 doi: 10.1016/B978-0-12-804003-4.00008-6
|
| 17 |
E. Van Cutsem, K. Muro, D. Cunningham, G. Bodoky, A. Sobrero, S. Cascinu, J. Ajani, S.C. Oh, S.E. Al-Batran, Z.A. Wainberg, S.R. Wijayawardana, S. Melemed, D. Ferry, R.R. Hozak, A. Ohtsu. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. European Journal of Cancer 2020; 127: 150 doi: 10.1016/j.ejca.2019.10.026
|
| 18 |
Daniela Cornelia Lazăr, Sorina Tăban, Marioara Cornianu, Alexandra Faur, Adrian Goldiş. New advances in targeted gastric cancer treatment. World Journal of Gastroenterology 2016; 22(30): 6776-6799 doi: 10.3748/wjg.v22.i30.6776
|
| 19 |
Mark A. Baxter, Fearghas Middleton, Hannah P. Cagney, Russell D. Petty. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. British Journal of Cancer 2021; 125(8): 1068 doi: 10.1038/s41416-021-01425-7
|
| 20 |
Xinlin Yu. Evaluation of the efficacy and safety of toripalimab combination therapy for treatment of advanced gastric cancer: a meta-analysis. International Journal of Clinical and Experimental Pathology 2025; 18(3): 96 doi: 10.62347/GZOW5960
|
| 21 |
Jianming Xu, Jieer Ying, Rongrui Liu, Jun Wu, Feng Ye, Nong Xu, Yanqiao Zhang, Rusen Zhao, Xiaojun Xiang, Jianhong Wang, Xiaoyan Lin, Huiting Xu, Shegan Gao, Suxia Luo, Baohong Guo, Xionghui Li, Yangzhi Su, Qian Wang. KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer. European Journal of Cancer 2023; 178: 1 doi: 10.1016/j.ejca.2022.10.004
|
| 22 |
Ahmed Katsha, Lihong Wang, Janet Arras, Omar M. Omar, Jeffrey Ecsedy, Abbes Belkhiri, Wael El-Rifai. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells. Clinical Cancer Research 2017; 23(14): 3756 doi: 10.1158/1078-0432.CCR-16-2141
|
| 23 |
Diana Galos, Loredana Balacescu, Radu Vidra, Daniel Sur. Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population. Life 2023; 13(12): 2300 doi: 10.3390/life13122300
|
| 24 |
Shuqin Jia, Tingting Qu, Xiaohong Wang, Mengmeng Feng, Yang Yang, Xuemin Feng, Ruiting Ma, Wenmei Li, Ying Hu, Yi Feng, Ke Ji, Ziyu Li, Wenguo Jiang, Jiafu Ji, Aamir Ahmad. KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer. PLOS ONE 2017; 12(4): e0175058 doi: 10.1371/journal.pone.0175058
|
| 25 |
Yung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doi. TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study. Cancer Research and Treatment 2018; 50(2): 398 doi: 10.4143/crt.2017.074
|
| 26 |
A. B. Rays, M. Yu. Fedyanin, D. V. Popov, I. A. Pokataev, M. A. Lyadova, L. G. Zhukova, D. L. Stroyakovsky, M. V. Volkonsky, R. Sh. Abdulaeva, I. A. Karasev, A. A. Tryakin. Prognostic and predictive factors in patients with metastatic gastric cancer treated with immune checkpoint inhibitors. Surgery and Oncology 2024; 14(4): 73 doi: 10.17650/2949-5857-2024-14-4-73-85
|
| 27 |
A. Scott Paulson, Lisa M. Hess, Astra M. Liepa, Zhanglin Lin Cui, Kathleen M. Aguilar, Jamyia Clark, William Schelman. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer 2018; 21(5): 831 doi: 10.1007/s10120-018-0796-z
|
| 28 |
Jane E. Rogers, Lianchun Xiao, Fatemeh G. Amlashi, Elena Elimova, Mariela A. Blum Murphy, Elizabeth Sanders, Namita Shanbhag, Irene Thomas, Jaffer A. Ajani. Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. Oncology 2019; 96(5): 252 doi: 10.1159/000496978
|
| 29 |
Anastasia Rays, Мikhail Fedyanin, Dmitriy Popov, Ilya Pokataev, Мarina Lyadova, Lyudmila Zhukova, Daniil Stroyakovskiy, Мikhail Volkonskiy, Natalya Besova, Аlexey Tryakin. Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study. Exploration of Digestive Diseases 2025; doi: 10.37349/edd.2025.100568
|
| 30 |
Zidan Zhao, Tsz Kin Mak, Yuntao Shi, Kuan Li, Mingyu Huo, Changhua Zhang. Integrative analysis of cancer-associated fibroblast signature in gastric cancer. Heliyon 2023; 9(9): e19217 doi: 10.1016/j.heliyon.2023.e19217
|
| 31 |
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database of Systematic Reviews 2020; 2020(11) doi: 10.1002/14651858.CD012078.pub2
|
| 32 |
E. Fountzilas, J. Souglakos, J. Alafis, K. Dadouli, A. Koumarianou, N. Tsoukalas, A. Nikolaidi, D. Mauri, M. Karagianni, A. Anna, A. Psyrri, G. Rigakos, A. Avgerinos, M. Theochari, D. Pectasides, G. Oikonomopoulos, A. Vagionas, P. Papakostas, A. Christopoulou, G. Fountzilas, Z. Saridaki. Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer. ESMO Gastrointestinal Oncology 2024; 5: 100073 doi: 10.1016/j.esmogo.2024.100073
|
| 33 |
Federico Longo, Mónica Jorge, Ricardo Yaya, Ana Fernández Montes, Nieves Martínez Lago, Elena Brozos, Jorge Aparicio, Guillermo Quintero, Eduardo Ceballos, Elvira Buxó, Ana Maria Lopez, Maria Luz Pellón, Raquel Molina, Laura Diaz-Paniagua, Paula Cerdà, Pedro Lopez Leiva, Alfonso Martín Carnicero, Antía Cousillas, Lorena Paris, Beatriz García-Paredes, Carlos Romero, María Ortega, Alberto Molero, Sergio de la Torre, Min-Hua Jen, Silvia Díaz-Cerezo. Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study. Future Oncology 2021; 17(14): 1777 doi: 10.2217/fon-2020-1216
|